tert-butyl ((1-(hydroxymethyl)cyclohexyl)methyl)carbamate | 223763-92-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: tert-butyl ((1-(hydroxymethyl)cyclohexyl)methyl)carbamate
• 英文别名: N-Boc-1-(hydroxymethyl)-1-cyclohexanemethanamine；tert-butyl N-[[1-(hydroxymethyl)cyclohexyl]methyl]carbamate
• CAS: 223763-92-6
• 化学式: C₁₃H₂₅NO₃
• 分子量: 243.346
• InChiKey: MOTUOQOPVFFWAT-UHFFFAOYSA-N

物化性质

• 沸点：
  362.2±15.0 °C(Predicted)
• 密度：
  1.016±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tert-butyl ((1-(hydroxymethyl)cyclohexyl)methyl)carbamate 在 碳酸氢钠 、 间氯过氧苯甲酸 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 [1-(Benzothiazole-2-sulfonylmethyl)-cyclohexylmethyl]-carbamic acid tert-butyl ester
  参考文献：
  名称：

  Carboxylate bioisosteres of gabapentin

  摘要：

  A series of carboxylate bioisosteres of structures related to gabapentin 1 have been prepared. When the carboxylate was replaced by a tetrazole, this group was recognized by the alpha(2)-delta protein. Further characterization Of alpha(2)-delta binding compounds 14a and 14b revealed a similar pattern of functional in vitro and in vivo activity to gabapentin 1. (C) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.05.016
• 作为产物：
  描述：

  1-氰基环己烷羧酸乙酯 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 52.0h， 生成 tert-butyl ((1-(hydroxymethyl)cyclohexyl)methyl)carbamate
  参考文献：
  名称：

  新型 P2X7 拮抗剂的设计、合成和体外评估。

  摘要：

  由于 P2X7 受体在炎症和免疫细胞信号传导中的重要作用，它是治疗各种疾病的有希望的靶点。这项工作描述了一系列带有多种支架的新型衍生物作为有效的 P2X7 拮抗剂的设计、合成和体外评估。我们的方法基于已报道的（金刚烷-1-基）甲基苯甲酰胺的结构修饰，能够抑制受体激活。金刚烷部分和酰胺键被替换，并通过基于配体的药效团模型评估替换。通过双电极电压钳实验评估合成类似物的拮抗效力，使用非洲爪蟾表达人 P2X7 受体的卵母细胞。SAR 研究表明，用芳基-环己基部分取代金刚烷环是对抗 P2X7 阳离子通道激活的最有效拮抗剂，类似物 2-氯-N- [1-(3-(硝基氧基甲基)苯基)环己基)甲基]苯甲酰胺 ( 56 ) 表现出最佳效力，IC 50值为 0.39 μM。

  DOI：

  10.1002/cmdc.202000303

文献信息

• Brønsted Acid-Initiated Formal [1,3]-Rearrangement Dictated by β-Substituted Ene-Aldimines
  作者：Chanantida Jongwohan、Yasushi Honda、Toshiyasu Suzuki、Takeshi Fujinami、Kiyohiro Adachi、Norie Momiyama

  DOI：10.1021/acs.orglett.9b01533

  日期：2019.7.5

  ene-aldimines is a useful reaction for affording homoallylic amines. Despite their utilities in synthetic chemistry, the rearrangement for accessing homoallylic amines substituted at the 2-position remains elusive. In this study, the Brønsted acid-initiated formal [1,3]-rearrangement of ene-aldimines was developed to synthesize 2,4,4-substituted homoallylic amines that were otherwise inaccessible previously

  烯丙二胺的重排是用于提供均烯丙基胺的有用反应。尽管它们在合成化学中有用，但仍难以获得在2-位取代的均烯丙基胺的重排。在这项研究中，开发了由Brønsted酸引发的烯丙二胺的正式[1,3]重排，以合成2,4,4-取代的均烯丙基胺，而这在以前是无法获得的。我们的研究揭示了一个分子间途径，其中重排通过质子化介导的2-氮杂铝阳离子进行。
• 신규한 PIM 키나아제 억제 화합물 및 이의 용도
  申请人：제일약품주식회사

  公开号：KR20230154382A

  公开（公告）日：2023-11-08

  본 발명은 신규한 PIM 키나아제 억제제 및 이의 용도에 관한 것으로, 보다 상세하게는 PIM 키나아제 억제 활성을 가지는 신규한 화합물 및 이를 포함하는 PIM 키나아제 활성과 관련된 질환의 예방, 개선 또는 치료용 조성물에 관한 것이다. 본 발명의 화합물은 심장독성이 낮으면서도, 효과적으로 PIM 키나아제 억제 활성을 가지는 것을 확인하였으므로, 본 발명의 화합물은 PIM 키나아제 활성과 관련된 암, 자가면역질환, 골수 증식성 장애 또는 죽상동맥경화증과 같은 다양한 질환의 예방, 개선 또는 치료용 조성물로 유용하게 사용될 수 있다.

  本发明涉及新型PIM激酶抑制剂及其用途，更具体地说，涉及具有PIM激酶抑制活性的新型化合物和包含这些化合物的预防、改善或治疗与PIM激酶活性相关疾病的组合物。由于已发现本发明化合物具有有效的 PIM 激酶抑制活性，且心脏毒性低，因此本发明化合物可用于预防、改善或治疗与 PIM 激酶活性相关的各种疾病（如癌症、自身免疫性疾病、骨髓增生性疾病或动脉粥样硬化）的组合物中。
• Phenyl substituted pyrazoles as modulators of RORγt
  申请人：Janssen Pharmaceutica NV

  公开号：US10975037B2

  公开（公告）日：2021-04-13

  The present invention comprises compounds of Formula I. wherein: R1, R3, R4, R5, R6, R7, R8, and Q are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-γ-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

  本发明包括式 I 的化合物。 其中 R1、R3、R4、R5、R6、R7、R8 和 Q 的定义见说明书。 本发明还包括一种治疗或改善 ROR-γ-t 介导的综合征、紊乱或疾病的方法，其中综合征、紊乱或疾病选自由类风湿性关节炎、银屑病关节炎和银屑病组成的组。本发明还包括一种通过施用治疗有效量的至少一种式 I 化合物来调节哺乳动物体内 RORγt 活性的方法。
• Phenyl and pyridinyl substituted imidazoles as modulators of RORγT
  申请人：Janssen Pharmaceutica NV

  公开号：US11345666B2

  公开（公告）日：2022-05-31

  The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, Ra, Rb, Q1, and Q2 are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-γ-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

  本发明包括式 I 的化合物。 其中 R1、R2、R3、R4、R5、Ra、Rb、Q1 和 Q2 在说明书中定义。 本发明还包括一种治疗或改善 ROR-γ-t 介导的综合征、紊乱或疾病的方法，其中综合征、紊乱或疾病选自由类风湿性关节炎、银屑病关节炎和银屑病组成的组。本发明还包括一种通过施用治疗有效量的至少一种式 I 化合物来调节哺乳动物体内 RORγt 活性的方法。
• 2-Arylimino-5,6-dihydro-4H-1,3-thiazines as a new class of cannabinoid receptor agonists. Part 3: Synthesis and activity of isosteric analogs
  作者：Hiroyuki Kai、Yasuhide Morioka、Yuji Koriyama、Kazuya Okamoto、Yasushi Hasegawa、Maki Hattori、Katsumi Koike、Hiroki Chiba、Shunji Shinohara、Yuka Iwamoto、Kohji Takahashi、Norihiko Tanimoto

  DOI：10.1016/j.bmcl.2008.10.070

  日期：2008.12

  Structure-activity relationships and efforts to optimize the pharmacokinetic pro. le of isosteric analogs of 2-arylimino-5,6-dihydro-4H-1,3-thiazines as cannabinoid receptor agonists are described. Among those examined, compound 25 showed potent affinity for cannabinoid receptor 1 (CB1) and receptor 2 (CB2). This compound displayed oral bioavailability and analgesic activity. (C) 2008 Elsevier Ltd. All rights reserved.